Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Augmenting the action of levodopa Rao SK; Vakil SD; Calne DB; Hilson APostgrad Med J 1972[Nov]; 48 (565): 653-6Various pharmacological approaches to potentiate the therapeutic actions of levodopa and reduce side-effects are reviewed. Of currently available drugs, anticholinergic agents and amantadine have been studied extensively. Inhibition of extracerebral decarboxylase appears to be the most promising new area of investigation, though experience is at present limited. Other methods discussed include inhibition of enzymes catechol-O-methyl transferase, monoamine oxidase and dopamine beta hydroxylase. Conflicting evidence on 3-O-methyldopa is discussed.|Amantadine/therapeutic use[MESH]|Antacids/therapeutic use[MESH]|Apomorphine/adverse effects[MESH]|Carboxy-Lyases/antagonists & inhibitors[MESH]|Catechol O-Methyltransferase Inhibitors[MESH]|Dihydroxyphenylalanine/administration & dosage/adverse effects/*therapeutic use[MESH]|Dopamine beta-Hydroxylase/antagonists & inhibitors[MESH]|Drug Synergism[MESH]|Humans[MESH]|Methyldopa/therapeutic use[MESH]|Monoamine Oxidase Inhibitors/therapeutic use[MESH]|Parasympatholytics/therapeutic use[MESH]|Parkinson Disease/*drug therapy[MESH] |